Sonomed Escalon™ to Introduce New VuMax™ HDB High-Resolution B-Scan System at ASCRS 2013

Sonomed Escalon™ to Introduce New VuMax™ HDB High-Resolution B-Scan System at
                                  ASCRS 2013

PR Newswire

WAYNE, Pa., April 19, 2013

WAYNE, Pa., April 19, 2013 /PRNewswire/ -- Escalon® Medical Corp. (Nasdaq:
ESMC) today announced its Sonomed Escalon™ group will be introducing its new
VuMax™ HDB B-scan system at the Annual Meeting of the American Society of
Cataract and Refractive Surgeons (ASCRS) in San Francisco, CA April 20-23,
2013. The VuMax™ HDB will become part of the expanded VuMax™ line of
high-resolution ophthalmic ultrasound systems, already known for outstanding
UBM imaging.

"The VuMax™ HDB adds to Sonomed Escalon's repertoire of ophthalmic ultrasound
systems and specifically addresses the needs of retinal and certain other
practices for high-resolution B-scan imaging of the posterior segment of the
eye," noted Barry Durante, Sonomed Escalon's President. "Based upon clinical
feedback received thus far, we believe the B-scan image quality will clearly
set this system apart and enable Sonomed Escalon to serve a previously
untapped market."

Founded in 1987, Escalon Medical Corp. ( develops markets
and distributes ophthalmic diagnostic and surgical products. The Company seeks
to further develop and diversify its product offering through internal
development programs, strategic partnerships, and acquisition of technology so
as to best leverage the Company's distribution capabilities, although such
development, partnerships or acquisitions may not occur. The Company has
headquarters in Wayne, Pennsylvania and operations in Lake Success, New York,
New Berlin, Wisconsin and Stoneham, Massachusetts.

Note: This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about the Company's future prospects. These statements
are based on the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether the Company is able to:

  oimplement its growth and marketing strategies, improve upon the operations
    of the Company business units, including the ability to make acquisitions
    and the integration of any acquisitions it may undertake, if any, of which
    there can be no assurance,
  ogrow our remaining ophthalmic business unit,
  oimplement cost reductions,
  ogenerate cash,
  oidentify, finance and enter into business relationships and acquisitions.

Other factors include uncertainties and risks related to:

  onew product development, commercialization, manufacturing and market
    acceptance of new products,
  omarketing acceptance of existing products in new markets,
  oresearch and development activities, including failure to demonstrate
    clinical efficacy,
  odelays or approvals by regulatory authorities, scientific and technical
    advances by the Company or third parties,
  ointroduction of competitive products,
  oability to reduce staffing and other costs and retain benefit of prior
  othird party reimbursement and physician training, and
  ogeneral economic conditions.

Further information about these and other relevant risks and uncertainties may
be found in the Company's report on Form 10- K for year ended June 30, 2012,
and its other filings with the Securities and Exchange Commission, all of
which are available from the Securities and Exchange Commission as well as
other sources.

SOURCE Escalon Medical Corp.

Contact: Richard J. DePiano, Chairman and CEO, 610/688-6830
Press spacebar to pause and continue. Press esc to stop.